ArticleJournal of virology2017
A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza.
Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate WithFrontiers in immunology · 2021Trial
- DNA vaccines targeting hemagglutinin from 18 subtypes of influenza A virus to antigen-presenting cells confer broad protection.Molecular therapy. Nucleic acids · 2026Article
- An HLAII-targeted DNA vaccine against influenza H7N9 protected mice and ferrets from a virus challenge.NPJ vaccines · 2025Article
- Heterologous signal peptide grafting enhances the immune efficacy of Salmonella vectors delivering hemagglutinin against H7N9 avian influenza virus.Veterinary research · 2025Article
- Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins.Nature communications · 2024Article
- Neuraminidase delivered as an APC-targeted DNA vaccine induces protective antibodies against influenza.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Recent advances in antigen targeting to antigen-presenting cells in veterinary medicine.Frontiers in immunology · 2023Review
- Integration of T helper and BCR signals governs enhanced plasma cell differentiation of memory B cells by regulation of CD45 phosphatase activity.Cell reports · 2021Article
- More Than Just Gene Therapy Vectors: Lentiviral Vector Pseudotypes for Serological Investigation.Viruses · 2021Review
- APC-Targeted DNA Vaccination Against Reticulocyte-Binding Protein Homolog 5 InducesFrontiers in immunology · 2021Article
- Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief.Frontiers in immunology · 2021Article
- Stable Immune Response Induced by Intradermal DNA Vaccination by a Novel Needleless Pyro-Drive Jet Injector.AAPS PharmSciTech · 2019Article
- Review
- Potential Role of Rainbow Trout Erythrocytes as Mediators in the Immune Response Induced by a DNA Vaccine in Fish.Vaccines · 2019Article
- A Review of DNA Vaccines Against Influenza.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zoonotic influenza H7 viral infections have a case fatality rate of about 40%. Currently, no or limited human to human spread has occurred, but we may be facing a severe pandemic threat if the virus acquires the ability to transmit between humans. Novel vaccines that can be rapidly produced for global distribution are urgently needed, and DNA vaccines may be the only type of vaccine that allows for the speed necessary to quench an emerging pandemic. Here, we constructed DNA vaccines encoding the hemagglutinin (HA) from influenza A/chicken/Italy/13474/99 (H7N1). In order to increase the efficacy of DNA vaccination, HA was targeted to either major histocompatibility complex class II molecules or chemokine receptors 1, 3, and 5 (CCR1/3/5) that are expressed on antigen-presenting cells (APC). A single DNA vaccination with APC-targeted HA significantly increased antibody levels in sera compared to nontargeted control vaccines. The antibodies were confirmed neutralizing in an H7 pseudotype-based neutralization assay. Furthermore, the APC-targeted vaccines increased the levels of antigen-specific cytotoxic T cells, and a single DNA vaccination could confer protection against a lethal challenge with influenza A/turkey/Italy/3889/1999 (H7N1) in mice. In conclusion, we have developed a vaccine that rapidly could contribute protection against a pandemic threat from avian influenza.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.